Deep learning based tissue analysis predicts outcome in colorectal cancer

Image-based machine learning and deep learning in particular has recently shown expert-level accuracy in medical image classification. In this study, we combine convolutional and recurrent architectures to train a deep network to predict colorectal cancer outcome based on images of tumour tissue samples. The novelty of our approach is that we directly predict patient outcome, without any intermediate tissue classification. We evaluate a set of digitized haematoxylin-eosin-stained tumour tissue microarray (TMA) samples from 420 colorectal cancer patients with clinicopathological and outcome data available. The results show that deep learning-based outcome prediction with only small tissue areas as input outperforms (hazard ratio 2.3; CI 95% 1.79-3.03; AUC 0.69) visual histological assessment performed by human experts on both TMA spot (HR 1.67; CI 95% 1.28-2.19; AUC 0.58) and whole-slide level (HR 1.65; CI 95% 1.30-2.15; AUC 0.57) in the stratification into low-and high-risk patients. Our results suggest that state-of-the-art deep learning techniques can extract more prognostic information from the tissue morphology of colorectal cancer than an experienced human observer.Peer reviewe

INTEGRATIVE ANALYSIS OF OMICS DATA IN ADULT GLIOMA AND OTHER TCGA CANCERS TO GUIDE PRECISION MEDICINE

Transcriptomic profiling and gene expression signatures have been widely applied as effective approaches for enhancing the molecular classification, diagnosis, prognosis or prediction of therapeutic response towards personalized therapy for cancer patients. Thanks to modern genome-wide profiling technology, scientists are able to build engines leveraging massive genomic variations and integrating with clinical data to identify “at risk” individuals for the sake of prevention, diagnosis and therapeutic interventions. In my graduate work for my Ph.D. thesis, I have investigated genomic sequencing data mining to comprehensively characterise molecular classifications and aberrant genomic events associated with clinical prognosis and treatment response, through applying high-dimensional omics genomic data to promote the understanding of gene signatures and somatic molecular alterations contributing to cancer progression and clinical outcomes. Following this motivation, my dissertation has been focused on the following three topics in translational genomics. 1) Characterization of transcriptomic plasticity and its association with the tumor microenvironment in glioblastoma (GBM). I have integrated transcriptomic, genomic, protein and clinical data to increase the accuracy of GBM classification, and identify the association between the GBM mesenchymal subtype and reduced tumorpurity, accompanied with increased presence of tumor-associated microglia. Then I have tackled the sole source of microglial as intrinsic tumor bulk but not their corresponding neurosphere cells through both transcriptional and protein level analysis using a panel of sphere-forming glioma cultures and their parent GBM samples.FurthermoreI have demonstrated my hypothesis through longitudinal analysis of paired primary and recurrent GBM samples that the phenotypic alterations of GBM subtypes are not due to intrinsic proneural-to-mesenchymal transition in tumor cells, rather it is intertwined with increased level of microglia upon disease recurrence. Collectively I have elucidated the critical role of tumor microenvironment (Microglia and macrophages from central nervous system) contributing to the intra-tumor heterogeneity and accurate classification of GBM patients based on transcriptomic profiling, which will not only significantly impact on clinical perspective but also pave the way for preclinical cancer research. 2) Identification of prognostic gene signatures that stratify adult diffuse glioma patientsharboring1p/19q co-deletions. I have compared multiple statistical methods and derived a gene signature significantly associated with survival by applying a machine learning algorithm. Then I have identified inflammatory response and acetylation activity that associated with malignant progression of 1p/19q co-deleted glioma. In addition, I showed this signature translates to other types of adult diffuse glioma, suggesting its universality in the pathobiology of other subset gliomas. My efforts on integrative data analysis of this highly curated data set usingoptimizedstatistical models will reflect the pending update to WHO classification system oftumorsin the central nervous system (CNS). 3) Comprehensive characterization of somatic fusion transcripts in Pan-Cancers. I have identified a panel of novel fusion transcripts across all of TCGA cancer types through transcriptomic profiling. Then I have predicted fusion proteins with kinase activity and hub function of pathway network based on the annotation of genetically mobile domains and functional domain architectures. I have evaluated a panel of in -frame gene fusions as potential driver mutations based on network fusion centrality hypothesis. I have also characterised the emerging complexity of genetic architecture in fusion transcripts through integrating genomic structure and somatic variants and delineating the distinct genomic patterns of fusion events across different cancer types. Overall my exploration of the pathogenetic impact and clinical relevance of candidate gene fusions have provided fundamental insights into the management of a subset of cancer patients by predicting the oncogenic signalling and specific drug targets encoded by these fusion genes. Taken together, the translational genomic research I have conducted during my Ph.D. study will shed new light on precision medicine and contribute to the cancer research community. The novel classification concept, gene signature and fusion transcripts I have identified will address several hotly debated issues in translational genomics, such as complex interactions between tumor bulks and their adjacent microenvironments, prognostic markers for clinical diagnostics and personalized therapy, distinct patterns of genomic structure alterations and oncogenic events in different cancer types, therefore facilitating our understanding of genomic alterations and moving us towards the development of precision medicine

A Comparative Study for Methodologies and Algorithms Used In Colon Cancer Diagnoses and Detection

Colon cancer is also referred to as colorectal cancer; it is a kind of cancer that starts with colon damage to the large intestine in the last section of the digestive tract. Elderly people typically suffer from colon cancer, but this may occur at any age. It normally starts as a little, noncancerous (benign) mass of cells named polyps that structure within the colon. After a period of time these polyps can turn into advanced malignant tumors that attack the human body and some of these polyps can become colon cancers. So far, no concrete causes have been identified and the complete cancer treatment is very difficult to be detected by doctors in the medical field. Colon cancer often has no symptoms in an early stage so detecting it at this stage is curable but colorectal cancer diagnosis in the final stages (stage IV), gives it the opportunity to spread into different pieces of the body, which are difficult to treat successfully, and the person\u27s opportunities of survival become much lower. False diagnosis of colorectal cancer which means wrong treatment for patients with long-term infections and they will be suffering from colon cancer this causing the death for these patients. Also, cancer treatment needs more time and a lot of money. This paper provides a comparative study for methodologies and algorithms used in the colon cancer diagnoses and detection this can help for proposing a prediction for risk levels of colon cancer disease using CNN algorithm of deep learning (Convolutional Neural Networks Algorithm)

The use of knowledge discovery databases in the identification of patients with colorectal cancer

Colorectal cancer is one of the most common forms of malignancy with 35,000 new patients diagnosed annually within the UK. Survival figures show that outcomes are less favourable within the UK when compared with the USA and Europe with 1 in 4 patients having incurable disease at presentation as of data from 2000.Epidemiologists have demonstrated that the incidence of colorectal cancer is highest on the industrialised western world with numerous contributory factors. These range from a genetic component to concurrent medical conditions and personal lifestyle. In addition, data also demonstrates that environmental changes play a significant role with immigrants rapidly reaching the incidence rates of the host country.Detection of colorectal cancer remains an important and evolving aspect of healthcare with the aim of improving outcomes by earlier diagnosis. This process was initially revolutionised within the UK in 2002 with the ACPGBI 2 week wait guidelines to facilitate referrals form primary care and has subsequently seen other schemes such as bowel cancer screening introduced to augment earlier detection rates. Whereas the national screening programme is dependent on FOBT the standard referral practice is dependent upon a number of trigger symptoms that qualify for an urgent referral to a specialist for further investigations. This process only identifies 25-30% of those with colorectal cancer and remains a labour intensive process with only 10% of those seen in the 2 week wait clinics having colorectal cancer.This thesis hypothesises whether using a patient symptom questionnaire in conjunction with knowledge discovery techniques such as data mining and artificial neural networks could identify patients at risk of colorectal cancer and therefore warrant urgent further assessment. Artificial neural networks and data mining methods are used widely in industry to detect consumer patterns by an inbuilt ability to learn from previous examples within a dataset and model often complex, non-linear patterns. Within medicine these methods have been utilised in a host of diagnostic techniques from myocardial infarcts to its use in the Papnet cervical smear programme for cervical cancer detection.A linkert based questionnaire of those attending the 2 week wait fast track colorectal clinic was used to produce a ‘symptoms’ database. This was then correlated with individual patient diagnoses upon completion of their clinical assessment. A total of 777 patients were included in the study and their diagnosis categorised into a dichotomous variable to create a selection of datasets for analysis. These data sets were then taken by the author and used to create a total of four primary databases based on all questions, 2 week wait trigger symptoms, Best knowledge questions and symptoms identified in Univariate analysis as significant. Each of these databases were entered into an artificial neural network programme, altering the number of hidden units and layers to obtain a selection of outcome models that could be further tested based on a selection of set dichotomous outcomes. Outcome models were compared for sensitivity, specificity and risk. Further experiments were carried out with data mining techniques and the WEKA package to identify the most accurate model. Both would then be compared with the accuracy of a colorectal specialist and GP.Analysis of the data identified that 24% of those referred on the 2 week wait referral pathway failed to meet referral criteria as set out by the ACPGBI. The incidence of those with colorectal cancer was 9.5% (74) which is in keeping with other studies and the main symptoms were rectal bleeding, change in bowel habit and abdominal pain. The optimal knowledge discovery database model was a back propagation ANN using all variables for outcomes cancer/not cancer with sensitivity of 0.9, specificity of 0.97 and LR 35.8. Artificial neural networks remained the more accurate modelling method for all the dichotomous outcomes.The comparison of GP’s and colorectal specialists at predicting outcome demonstrated that the colorectal specialists were the more accurate predictors of cancer/not cancer with sensitivity 0.27 and specificity 0.97, (95% CI 0.6-0.97, PPV 0.75, NPV 0.83) and LR 10.6. When compared to the KDD models for predicting the same outcome, once again the ANN models were more accurate with the optimal model having sensitivity 0.63, specificity 0.98 (95% CI 0.58-1, PPV 0.71, NPV 0.96) and LR 28.7.The results demonstrate that diagnosis colorectal cancer remains a challenging process, both for clinicians and also for computation models. KDD models have been shown to be consistently more accurate in the prediction of those with colorectal cancer than clinicians alone when used solely in conjunction with a questionnaire. It would be ill conceived to suggest that KDD models could be used as a replacement to clinician- patient interaction but they may aid in the acceleration of some patients for further investigations or ‘straight to test’ if used on those referred as routine patients

A Survey on Deep Learning in Medical Image Analysis

Deep learning algorithms, in particular convolutional networks, have rapidly become a methodology of choice for analyzing medical images. This paper reviews the major deep learning concepts pertinent to medical image analysis and summarizes over 300 contributions to the field, most of which appeared in the last year. We survey the use of deep learning for image classification, object detection, segmentation, registration, and other tasks and provide concise overviews of studies per application area. Open challenges and directions for future research are discussed.Comment: Revised survey includes expanded discussion section and reworked introductory section on common deep architectures. Added missed papers from before Feb 1st 201

A Deep Learning Approach for Multi-Omics Data Integration to Diagnose Early-Onset Colorectal Cancer

Colorectal cancer is one of the most common cancers and is a leading cause of death worldwide. It starts in the colon or the rectum, and they are often grouped together because they have many features in common. It has been noticed that colorectal cancer attacks young-onset patients who are less than 50 years of age in increasing rates lately. Rapid developments in omics technologies have led them to be highly regarded in the field of biomedical research for the early detection of cancer. Omics data revealed how different molecules and clinical features work together in the disease progression. However, Omics data sources are variants in nature and require careful preprocessing to be integrated. A convolutional neural network is a class of deep neural networks, commonly applied to analyze visual imagery. In this thesis, we propose a model that converts one-dimensional vectors of omics into RGB images to be integrated into the hidden layers of the convolutional neural network. The prediction model will allow all different omics to contribute to the decision making based on extracting the hidden interactions among these omics. These subsets of interacted omics can serve as potential biomarkers for young-onset colorectal cancer

Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis

Simple Summary Metastatic colorectal cancer (mCRC) has high incidence and mortality. Nevertheless, innovative biomarkers have been developed for predicting the response to therapy. We have examined the ability of learning methods to build prognostic and predictive models to predict response to chemotherapy, alone or combined with targeted therapy in mCRC patients, by targeting specific narrative publications. After a literature search, 26 original articles met inclusion and exclusion criteria and were included in the study. We showed that all investigations conducted in this field provided generally promising results in predicting the response to therapy or toxic side-effects, using a meta-analytic approach. We found that radiomics and molecular biomarker signatures were able to discriminate response vs. non-response by correctly identifying up to 99% of mCRC patients who were responders and up to 100% of patients who were non-responders. Our study supports the use of computer science for developing personalized treatment decision processes for mCRC patients. Tailored treatments for metastatic colorectal cancer (mCRC) have not yet completely evolved due to the variety in response to drugs. Therefore, artificial intelligence has been recently used to develop prognostic and predictive models of treatment response (either activity/efficacy or toxicity) to aid in clinical decision making. In this systematic review, we have examined the ability of learning methods to predict response to chemotherapy alone or combined with targeted therapy in mCRC patients by targeting specific narrative publications in Medline up to April 2022 to identify appropriate original scientific articles. After the literature search, 26 original articles met inclusion and exclusion criteria and were included in the study. Our results show that all investigations conducted on this field have provided generally promising results in predicting the response to therapy or toxic side-effects. By a meta-analytic approach we found that the overall weighted means of the area under the receiver operating characteristic (ROC) curve (AUC) were 0.90, 95% C.I. 0.80-0.95 and 0.83, 95% C.I. 0.74-0.89 in training and validation sets, respectively, indicating a good classification performance in discriminating response vs. non-response. The calculation of overall HR indicates that learning models have strong ability to predict improved survival. Lastly, the delta-radiomics and the 74 gene signatures were able to discriminate response vs. non-response by correctly identifying up to 99% of mCRC patients who were responders and up to 100% of patients who were non-responders. Specifically, when we evaluated the predictive models with tests reaching 80% sensitivity (SE) and 90% specificity (SP), the delta radiomics showed an SE of 99% and an SP of 94% in the training set and an SE of 85% and SP of 92 in the test set, whereas for the 74 gene signatures the SE was 97.6% and the SP 100% in the training set

Predicting potential drugs and drug-drug interactions for drug repositioning

The purpose of drug repositioning is to predict novel treatments for existing drugs. It saves time and reduces cost in drug discovery, especially in preclinical procedures. In drug repositioning, the challenging objective is to identify reasonable drugs with strong evidence. Recently, benefiting from various types of data and computational strategies, many methods have been proposed to predict potential drugs. Signature-based methods use signatures to describe a specific disease condition and match it with drug-induced transcriptomic profiles. For a disease signature, a list of potential drugs is produced based on matching scores. In many studies, the top drugs on the list are identified as potential drugs and verified in various ways. However, there are a few limitations in existing methods: (1) For many diseases, especially cancers, the tissue samples are often heterogeneous and multiple subtypes are involved. It is challenging to identify a signature from such a group of profiles. (2) Genes are treated as independent elements in many methods, while they may associate with each other in the given condition. (3) The disease signatures cannot identify potential drugs for personalized treatments. In order to address those limitations, I propose three strategies in this dissertation. (1) I employ clustering methods to identify sub-signatures from the heterogeneous dataset, then use a weighting strategy to concatenate them together. (2) I utilize human protein complex (HPC) information to reflect the dependencies among genes and identify an HPC signature to describe a specific type of cancer. (3) I use an HPC strategy to identify signatures for drugs, then predict a list of potential drugs for each patient. Besides predicting potential drugs directly, more indications are essential to enhance my understanding in drug repositioning studies. The interactions between biological and biomedical entities, such as drug-drug interactions (DDIs) and drug-target interactions (DTIs), help study mechanisms behind the repurposed drugs. Machine learning (ML), especially deep learning (DL), are frontier methods in predicting those interactions. Network strategies, such as constructing a network from interactions and studying topological properties, are commonly used to combine with other methods to make predictions. However, the interactions may have different functions, and merging them in a single network may cause some biases. In order to solve it, I construct two networks for two types of DDIs and employ a graph convolutional network (GCN) model to concatenate them together. In this dissertation, the first chapter introduces background information, objectives of studies, and structure of the dissertation. After that, a comprehensive review is provided in Chapter 2. Biological databases, methods and applications in drug repositioning studies, and evaluation metrics are discussed. I summarize three application scenarios in Chapter 2. The first method proposed in Chapter 3 considers the issue of identifying a cancer gene signature and predicting potential drugs. The k-means clustering method is used to identify highly reliable gene signatures. The identified signature is used to match drug profiles and identify potential drugs for the given disease. The second method proposed in Chapter 4 uses human protein complex (HPC) information to identify a protein complex signature, instead of a gene signature. This strategy improves the prediction accuracy in the experiments of cancers. Chapter 5 introduces the signature-based method in personalized cancer medicine. The profiles of a given drug are used to identify a drug signature, under the HPC strategy. Each patient has a profile, which is matched with the drug signature. Each patient has a different list of potential drugs. Chapter 6 propose a graph convolutional network with multi-kernel to predict DDIs. This method constructs two DDI kernels and concatenates them in the GCN model. It achieves higher performance in predicting DDIs than three state-of-the-art methods. In summary, this dissertation has proposed several computational algorithms for drug repositioning. Experimental results have shown that the proposed methods can achieve very good performance